Surufatinib before surgery for advanced thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer that has spread to nearby tissues or other parts of the body (locally advanced or metastatic). This includes papillary, follicular, or poorly differentiated thyroid cancer.
- You are between 14 and 75 years old.
- Your cancer can be measured on a CT or MRI scan (at least one measurable lesion).
- Your general health is good enough to perform daily activities (ECOG score 0 or 1).
- Your blood counts and organ function (kidney, liver) are within certain ranges — your doctor will check these.
- You have not taken a targeted anti-angiogenic drug (like Lenvatinib or Sorafenib) before, and you have not had other cancer treatment within the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
This trial tests a combination of two drugs—donafenib (a targeted therapy) and an immunotherapy (anti-PD-1 antibody)—given before surgery for locally advanced differentiated thyroid cancer. The goal is to shrink the tumor to make surgery easier and more complete. If you have this type of thyroid cancer that is hard to remove completely with surgery alone, this study may be an option.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
This trial tests a combination of two drugs (sinibolimab and lenvatinib) given before surgery. The goal is to shrink advanced thyroid cancer that cannot be fully removed otherwise, so that surgery can be more successful.
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
This Phase 2 trial studies whether surufatinib combined with chemotherapy given before surgery can shrink osteosarcoma and improve outcomes. It may help by attacking the tumor from more than one angle before the main treatment step.
Hear when a new Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.